MiMedx Group, Inc. reported a significant decline in financial performance for the second quarter of 2026, with net sales totaling $64.4 million, a decrease of 34.7% compared to $98.6 million in the same period last year. The decline was primarily driven by a 61.1% drop in Wound product sales, which fell to $25.1 million from $64.5 million. In contrast, the Surgical segment saw a 15.1% increase in sales, reaching $39.3 million, attributed to the continued adoption of products such as AMNIOFIX and AMNIOEFFECT. The company recorded a net loss of $14.8 million, or $0.10 per diluted share, compared to a net income of $9.6 million in the prior year.

The financial results reflect a broader trend, with total net sales for the first half of 2026 at $123.4 million, down 34.0% from $186.8 million in the first half of 2025. The decline in revenue was largely influenced by changes in Medicare reimbursement policies that adversely affected pricing and sales volumes for Wound products. Gross profit margins also suffered, decreasing to 69.0% from 81.1% year-over-year, primarily due to lower pricing in the Wound business and increased manufacturing costs.

Operationally, MiMedx has been focusing on strategic initiatives to align its cost structure with current business needs. The company implemented a reduction-in-force and other cost-cutting measures, resulting in a 6.8% decrease in selling, general, and administrative expenses, which totaled $59.8 million for the quarter. Additionally, the company repurchased approximately $13 million of its common stock under its Share Repurchase Plan, reflecting a commitment to return capital to shareholders while managing its financial resources prudently.

As of June 30, 2026, MiMedx reported $135.8 million in cash and cash equivalents, down from $166.1 million at the end of 2025. The company’s total current assets decreased to $205.4 million, while total current liabilities were reduced to $38.5 million. The company also has $17.3 million in long-term debt, with no outstanding borrowings under its $75 million revolving credit facility. Looking ahead, MiMedx aims to broaden its product portfolio and expand its market presence, particularly in international markets, while navigating the challenges posed by recent regulatory changes and market conditions.

About MIMEDX GROUP, INC.

MIMEDX Group, Inc. specializes in developing and distributing placental and animal-derived biologic tissues for wound care and surgical applications. Its core products include human placental allografts and xenografts used to treat chronic wounds, burns, and surgical sites. The company leverages proprietary processing methods, extensive scientific evidence, and regulatory compliance to serve healthcare providers globally, focusing on innovation, product diversification, and expanding clinical and international markets.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov